New research published by teams from Leicester, UK and Paris, France in collaboration with international partners from the US and Australia, has found a common genetic factor that confers a significant risk of atypical heart attacks in women. The genetic factor, located on chromosome 6, increases the risk of developing spontaneous coronary artery dissection (SCAD). […]Continue Reading ...
A group of researchers affiliated to the University of São Paulo (USP) – campus Ribeirão Preto, Brazil, used big data tools such as data mining and network analysis to develop a method to help scientists and companies identify technological routes, trends and partnerships in any knowledge area. For this purpose, it collected information from patent […]Continue Reading ...
What are Coagulation Factor Tests? Coagulation factors are proteins in the blood that help control bleeding. You have several different coagulation factors in your blood. When you get a cut or other injury that causes bleeding, your coagulation factors work together to form a blood clot. The clot stops you from losing too much blood. […]Continue Reading ...
Cambridge, Ma. – April 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved Vonvendi [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with […]Continue Reading ...
June 30, 2018 A research team found a novel function of fibroblast growth factor 2 (FGF2), a self-renewal factor for spermatogonial stem cell (SSC) which is the origin of the sperm production. Although it has demonstrated that both FGF2 and glial cell line-derived neurotrophic factor (GDNF) is indispensable for SSC self-renewal and survival in vitro, […]Continue Reading ...
FDA Approves Portola Pharmaceuticals’ Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) — Portola Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients […]Continue Reading ...
- Study suggests key role for glial cells in Parkinson’s disease
- Educational videos in clinical settings increase HPV vaccination rates among adolescents
- Better understanding of aggressive brain tumour
- Why is life expectancy in the U.S. going down? A Q&A
- The Electronics Industry Sees Money In Your Health
- Hypertension drug may improve effectiveness of ovarian cancer treatment
- Scientists reveal key mechanism in worms that controls cell’s response to stress
- How Patch Clamp Technology Can Benefit Ion Channel Research
- Researchers cultivate organoids that perfectly mimic blood vessels
- Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis
- Unraveling the genetic causes of skin cancer
- Higher percentages of saturated fat in low-carb diets may not harm cholesterol levels, new analysis suggests
- Using bottled or tap water impacts health benefits of green tea
- Best trained alert dogs have potential to improve Type 1 diabetes patients’ quality of life
- States with lower incidence of melanoma have higher mortality rates
- Pollution on the London Underground found to be dangerously high
- Breast cancer cells in mice coaxed to turn into harmless fat cells
- Study connects the genetic background of autistic spectrum disorders with stem cell dysfunction
- When activated, ‘social’ brain circuits inhibit feeding behavior in mice | News Center
- How Exercise May Help Keep Our Memory Sharp